Estrella Immunopharma (ESLA) Competitors $0.96 -0.05 (-4.95%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.02 (+2.08%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. EPRX, NKTX, FTLF, MGNX, GLSI, TARA, CABA, PLX, HURA, and CCCCShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Eupraxia Pharmaceuticals (EPRX), Nkarta (NKTX), FitLife Brands (FTLF), MacroGenics (MGNX), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), Cabaletta Bio (CABA), Protalix BioTherapeutics (PLX), TuHURA Biosciences (HURA), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Eupraxia Pharmaceuticals Nkarta FitLife Brands MacroGenics Greenwich LifeSciences Protara Therapeutics Cabaletta Bio Protalix BioTherapeutics TuHURA Biosciences C4 Therapeutics Estrella Immunopharma (NASDAQ:ESLA) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment. Does the MarketBeat Community believe in ESLA or EPRX? Eupraxia Pharmaceuticals received 2 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. CompanyUnderperformOutperformEstrella ImmunopharmaOutperform Votes2100.00% Underperform VotesNo VotesEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, ESLA or EPRX? Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.69Eupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-5.08 Is ESLA or EPRX more profitable? Estrella Immunopharma's return on equity of -195.77% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% Eupraxia Pharmaceuticals N/A -219.64%-96.00% Do insiders and institutionals have more ownership in ESLA or EPRX? 0.3% of Estrella Immunopharma shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to ESLA or EPRX? In the previous week, Estrella Immunopharma had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.93 beat Estrella Immunopharma's score of 0.43 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Estrella Immunopharma Neutral Eupraxia Pharmaceuticals Positive Which has more volatility and risk, ESLA or EPRX? Estrella Immunopharma has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Do analysts prefer ESLA or EPRX? Estrella Immunopharma currently has a consensus price target of $16.00, indicating a potential upside of 1,566.67%. Eupraxia Pharmaceuticals has a consensus price target of $10.50, indicating a potential upside of 172.02%. Given Estrella Immunopharma's higher probable upside, research analysts clearly believe Estrella Immunopharma is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryEstrella Immunopharma beats Eupraxia Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.72M$3.09B$5.58B$8.50BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-3.6932.6627.1919.64Price / SalesN/A455.28408.78152.17Price / CashN/A168.6838.3234.64Price / Book8.003.366.974.60Net Income-$7.31M-$72.35M$3.23B$248.06M7 Day Performance-9.87%0.32%-0.88%-1.02%1 Month Performance-6.81%17.21%7.81%3.51%1 Year Performance1.05%-17.83%31.53%12.68% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma2.1091 of 5 stars$0.96-5.0%$16.00+1,566.7%+9.1%$34.72MN/A-3.69N/AShort Interest ↑Gap DownEPRXEupraxia Pharmaceuticals2.1356 of 5 stars$3.92-0.5%$10.50+167.8%+43.2%$140.56MN/A-5.4529NKTXNkarta3.6579 of 5 stars$1.97+5.1%$14.67+646.4%-69.8%$139.43MN/A-1.05140Analyst ForecastFTLFFitLife Brands4.1777 of 5 stars$13.97-1.6%$20.50+46.7%-6.1%$131.19M$63.86M16.5320Short Interest ↑Gap UpMGNXMacroGenics3.8076 of 5 stars$2.11+28.4%$5.71+171.5%-68.9%$129.46M$152.43M-1.30430Options VolumeGap UpHigh Trading VolumeGLSIGreenwich LifeSciences2.2467 of 5 stars$9.52+0.7%$39.00+309.9%-33.8%$127.20MN/A-11.893Positive NewsTARAProtara Therapeutics2.4698 of 5 stars$3.30+0.8%$20.50+522.2%+23.0%$127.13MN/A-1.1730Positive NewsAnalyst RevisionCABACabaletta Bio2.8707 of 5 stars$2.51+5.8%$20.33+711.1%-85.2%$126.55MN/A-1.1650News CoverageAnalyst ForecastAnalyst RevisionGap DownPLXProtalix BioTherapeutics2.6048 of 5 stars$1.56+1.0%$15.00+864.6%+30.0%$123.79M$59.76M-11.96200HURATuHURA BiosciencesN/A$2.78-3.6%$12.67+356.5%N/A$122.48MN/A0.00N/ACCCCC4 Therapeutics2.1953 of 5 stars$1.70+0.9%$12.00+608.0%-67.3%$120.36M$39.78M-1.00150Positive News Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Competitors Nkarta Competitors FitLife Brands Competitors MacroGenics Competitors Greenwich LifeSciences Competitors Protara Therapeutics Competitors Cabaletta Bio Competitors Protalix BioTherapeutics Competitors TuHURA Biosciences Competitors C4 Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESLA Stock Free ESLA Stock Alerts